Pediatrix Medical Group (MD) director awarded 472 restricted shares and reports trust holdings

Rhea-AI Filing Summary

McEachin Thomas reported acquisition or exercise transactions in this Form 4 filing.

Pediatrix Medical Group director Thomas McEachin received a grant of 472 restricted shares of common stock on August 12, 2026 at a reference value of $26.50 per share under the Second Amended and Restated 2008 Incentive Compensation Plan. His directly held shares increased to 7,668, and he also reports 66,073 shares held indirectly through the Thomas A. McEachin Living Trust, with he and his spouse as trustees and beneficiaries. The restricted shares will vest on May 7, 2027.

Insider Trade Summary

Net Buyer: 472 shares

Net Buy 2 txns

Insider McEachin Thomas

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	472	$26.50	$13K
holding	Common Stock F2	--	--	--

Holdings After Transaction: Common Stock — 7,668 shares (Direct); Common Stock — 66,073 shares (Indirect, Thomas A. McEachin Living Trust dated April 17, 2025.)

Footnotes (2)

1. F1. Restricted shares granted pursuant to Issuer's Second Amended and Restated 2008 Incentive Compensation Plan, reflecting an increase to the annual equity award. Shares will vest on May 7, 2027.
2. F2. The reporting person and his spouse are trustees and beneficiaries of the trust that holds the reported securities.

Key Figures

Restricted shares granted: 472 shares Grant value per share: $26.50 per share Direct holdings after grant: 7,668 shares +3 more

6 metrics

Restricted shares granted 472 shares Equity award granted on August 12, 2026

Grant value per share $26.50 per share Reference value for restricted share grant

Direct holdings after grant 7,668 shares Common stock held directly by Thomas McEachin after transaction

Indirect trust holdings 66,073 shares Common stock held via Thomas A. McEachin Living Trust

Vesting date May 7, 2027 Date when the 472 restricted shares will vest

Trust date April 17, 2025 Date of Thomas A. McEachin Living Trust

Key Terms

Restricted shares, Second Amended and Restated 2008 Incentive Compensation Plan, indirect, Living Trust

4 terms

Restricted shares financial

"Restricted shares granted pursuant to Issuer's Second Amended and Restated 2008"

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

Second Amended and Restated 2008 Incentive Compensation Plan financial

"shares granted pursuant to Issuer's Second Amended and Restated 2008 Incentive"

indirect financial

"shares following transaction 66073.0000, direct_or_indirect I, nature_of_ownership"

Living Trust financial

"nature_of_ownership Thomas A. McEachin Living Trust dated April 17, 2025."

FAQ

What transaction did Pediatrix Medical Group (MD) director Thomas McEachin report?

Director Thomas McEachin reported receiving a grant of 472 restricted shares of Pediatrix Medical Group common stock on August 12, 2026. The award was made under the company’s Second Amended and Restated 2008 Incentive Compensation Plan as part of his annual equity award.

At what value were the restricted shares granted to MD director Thomas McEachin?

The 472 restricted shares granted to Thomas McEachin reference a value of $26.50 per share. This value is disclosed for the equity award accounting and does not represent an open-market purchase or sale of Pediatrix Medical Group stock by the director.

When will Thomas McEachin’s restricted Pediatrix Medical Group (MD) shares vest?

The 472 restricted shares granted to Thomas McEachin will vest on May 7, 2027. Vesting means the shares become fully earned and no longer subject to forfeiture conditions specified in Pediatrix Medical Group’s incentive compensation plan.

How many Pediatrix Medical Group (MD) shares does Thomas McEachin hold directly after this Form 4?

After the reported grant, Thomas McEachin holds 7,668 shares of Pediatrix Medical Group common stock directly. This figure reflects his direct ownership position following the award of 472 restricted shares on August 12, 2026.

What indirect Pediatrix Medical Group (MD) holdings does Thomas McEachin report?

Thomas McEachin reports 66,073 shares of Pediatrix Medical Group common stock held indirectly through the Thomas A. McEachin Living Trust dated April 17, 2025. He and his spouse serve as both trustees and beneficiaries of this trust.

Does this Pediatrix Medical Group (MD) Form 4 show any stock sales by Thomas McEachin?

The Form 4 reports a grant of 472 restricted shares and updated holdings, but no open-market stock sales or purchases. The transaction is coded as a grant or award acquisition, rather than a buy or sell of existing Pediatrix shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/14/2026 - 05:01 PM Accepted by SEC EDGAR 08/14/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McEachin Thomas

(Last) (First) (Middle)

1301 CONCORD TERRACE

(Street)

SUNRISE FLORIDA 33323

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pediatrix Medical Group, Inc. [ MD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2026		A(1)		472	A	$26.5	7,668	D
Common Stock								66,073	I	Thomas A. McEachin Living Trust dated April 17, 2025.(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted shares granted pursuant to Issuer's Second Amended and Restated 2008 Incentive Compensation Plan, reflecting an increase to the annual equity award. Shares will vest on May 7, 2027.

2. The reporting person and his spouse are trustees and beneficiaries of the trust that holds the reported securities.

	/s/ David Haddock, Attorney-in-Fact	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)